IO Biotech Announces Abstract Accepted for Mini Oral Presentation at IASLC 2023 World Conference on Lung Cancer
July 25, 2023 16:05 ET
|
IO Biotech
NEW YORK, July 25, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
IO Biotech Strengthens Executive Management and US Presence with Appointment of Qasim Ahmad, MD, as Chief Medical Officer
July 18, 2023 16:05 ET
|
IO Biotech
Eric Faulkner, currently Sr. Vice President, CMC, appointed as Chief Technical Officer NEW YORK, July 18, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical...
IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone
June 14, 2023 08:00 ET
|
IO Biotech
225 patients now randomized in global Phase 3 clinical trial for IO102-IO103, in combination with pembrolizumab, in patients with advanced melanoma; trial protocol calls for an interim analysis of...
IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program Lead
June 01, 2023 08:30 ET
|
IO Biotech
NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology...
IO Biotech to Present at the Jefferies Healthcare Conference
May 30, 2023 16:35 ET
|
IO Biotech
NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology...
IO Biotech Announces 2023 First-Quarter Results
May 11, 2023 16:05 ET
|
IO Biotech
The company expects to enroll 225 patients in its Phase 3 pivotal trial (IOB-013/KN-D18) in advanced melanoma by mid-2023 and to fully enroll the trial by the end of 2023.The Phase 3 trial protocol...
IO Biotech Announces 2022 Fourth-Quarter and Year-End Results
March 14, 2023 16:11 ET
|
IO Biotech
Enrollment in the company’s Phase 3 pivotal trial (IOB-013/KN-D18) in advanced melanoma accelerated in the second half of 2022; the company expects to enroll 75% of patients by mid-2023 and fully...
IO Biotech to Participate in March 2023 Investor Conferences
February 22, 2023 07:00 ET
|
IO Biotech
NEW YORK, Feb. 22, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® vaccine...
IO Biotech Announces Appointment of Devin Smith as General Counsel
January 23, 2023 08:00 ET
|
IO Biotech
NEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® vaccine...
IO Biotech Provides Business Update
January 09, 2023 07:05 ET
|
IO Biotech
Independent data monitoring committee recommends that the company’s Phase 3 trial evaluating IO102-IO103 in combination with pembrolizumab in first-line advanced melanoma patients continue without any...